Home THERAPY AREAS Where are we now? Emerging opportunities and challenges in the management of SHPT in patients with ND-CKD 18 February 2022 Nephrology and Rare Diseases CKD-MBD and SHPT Despite advances in our understanding, the optimal management of SHPT in ND-CKD remains challenging. There is a growing consensus that we must identify and treat patients with SHPT earlier in the course of the disease. However, target levels of PTH are unclear, as are the levels of vitamin D required to achieve sufficient PTH reduction. Based on a pivotal 2021 review by leading nephrologists Prof. Markus Ketteler (Robert-Bosch-Krankenhaus, Stuttgart, Germany) and Prof. Patrice Ambühl (Institut für Nephrologie, Zurich, Switzerland), this infographic provides expert insights into the rationale for SHPT and elevated PTH as a therapeutic target in ND-CKD. View article THERE IS MORE HERE Specialist information is located in this area. In order to be able to see this, you must verify yourself as a healthcare professional. ?